MRS Measurement of Glutamate and GABA Metabolism in Brain - Full Text View

Sponsor:	National Institute of Mental Health (NIMH)
Information provided by:	National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:	NCT00109174

Purpose

This study will use magnetic resonance spectroscopy (MRS) to measure in the brain the transfer of [13]C as it is naturally metabolized from glucose to specific chemical transmitters. From this method, we can measure the rate of production of an important excitatory neurotransmitter (glutamate) as well as an inhibitory neurotransmitter (GABA).

Condition	Intervention
Healthy	Procedure: Magnetic Resonance Spectroscopy

Study Type:	Interventional
Study Design:	Treatment
Official Title:	MRS (Magnetic Resonance Spectroscopy) Measurement of Glutamate and GABA Metabolism in Brain

Resource links provided by NLM:

Drug Information available for: Glutamic acid

U.S. FDA Resources

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment:	90
Study Start Date:	April 2005
Estimated Study Completion Date:	March 2006
Estimated Primary Completion Date:	March 2006 (Final data collection date for primary outcome measure)

Intervention Details:

N/A

Detailed Description:

(13)C is a stable (i.e., non-radioactive) isotope of carbon with a natural abundance of approximately 1%. Following infusion of [(13)C]glucose, in vivo MRS (magnetic resonance spectroscopy) can monitor the rate of flux of the (13)C atom from glucose to glutamate to glutamine. Thus, this procedure can provide measure of glutamate (GLU) and glutamine (GLN) turnover in brain. We have established parameters to obtain these measurements in nonhuman primate brain. The current protocol seeks approval to optimize MRS parameters for human brain using the GE 3T device.

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

INCLUSION CRITERIA:

Age: 18-65 years

Diagnosis: Healthy

EXCLUSION CRITERIA:

Serious medical illness (including diabetes) as determined from H& P or laboratory testing

Prescription psychotropic medication; drug free period must be greater than 3 weeks for anticholinergics and benzodiazepine and greater than 8 weeks for fluoxetine, antipsychotics, anticonvulsants

Claustrophobia

Pregnancy; women with child bearing potential will have pregnancy test to exclude pregnancy

Any condition that increases risk for MRI (e.g., pacemaker, metallic foreign body in the eye, etc.)

Unable to lay on one's back for MRI/MRS scans

Positive HIV test

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00109174

Contacts

Contact: Patient Recruitment and Public Liaison Office	(800) 411-1222	prpl@mail.cc.nih.gov
Contact: TTY	1-866-411-1010

Locations

United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike	Recruiting
Bethesda, Maryland, United States, 20892

Sponsors and Collaborators

National Institute of Mental Health (NIMH)

More Information

Additional Information:

NIH Clinical Center Detailed Web Page This link exits the ClinicalTrials.gov site

Publications:

Gruetter R, Novotny EJ, Boulware SD, Mason GF, Rothman DL, Shulman GI, Prichard JW, Shulman RG. Localized 13C NMR spectroscopy in the human brain of amino acid labeling from D-[1-13C]glucose. J Neurochem. 1994 Oct;63(4):1377-85.

Malloy CR, Sherry AD, Jeffrey FM. Analysis of tricarboxylic acid cycle of the heart using 13C isotope isomers. Am J Physiol. 1990 Sep;259(3 Pt 2):H987-95.

Shen J, Rothman DL. Magnetic resonance spectroscopic approaches to studying neuronal: glial interactions. Biol Psychiatry. 2002 Oct 1;52(7):694-700. Review.

Study ID Numbers:	050144, 05-M-0144
Study First Received:	April 22, 2005
Last Updated:	November 5, 2009
ClinicalTrials.gov Identifier:	NCT00109174 History of Changes
Health Authority:	United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):

Glutamate
Excitatory Amino Acid
Neurochemistry
GABA
Magnetic Resonance Spectroscopy

ClinicalTrials.gov processed this record on November 05, 2009